Serina Therapeutics (SER) CSO reports 1,700-share option-related trades filing

Rhea-AI Filing Summary

Serina Therapeutics, Inc.'s Chief Scientific Officer, Randall Moreadith, reported insider equity transactions dated 12/12/2025. He acquired 1,700 shares of common stock at $0.06 per share and, on the same date, sold 1,700 shares at a weighted average price of $3.2597, with sale prices ranging from $3.25 to $3.275. After these transactions, he directly held 0 shares of common stock.

The report also lists a stock option (right to buy) with an exercise price of $0.06 per share, covering 1,700 underlying shares in this transaction and expiring on 05/06/2031. Following the activity, 365,186 derivative securities (stock options) are shown as beneficially owned, and the stock options are described as fully vested.

Insider Trade Summary

Net Seller: 1,700 shares ($5,541)

Net Sell 3 txns

Insider Moreadith Randall

Role Chief Scientific Officer

Sold 1,700 shs ($6K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	1,700	$0.00	--
Exercise	Common Stock	1,700	$0.06	$102.00
Sale	Common Stock	1,700	$3.2597	$6K

Holdings After Transaction: Stock Option (right to buy) — 365,186 shares (Direct); Common Stock — 1,700 shares (Direct)

Footnotes (1)

1. The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.25 to $3.275. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. The stock options are fully vested.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Moreadith Randall

(Last) (First) (Middle)

601 GENOME WAY, SUITE 2001

(Street)

HUNTSVILLE AL 35806

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Serina Therapeutics, Inc. [ SER ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/12/2025		M		1,700	A	$0.06	1,700	D
Common Stock	12/12/2025		S		1,700	D	$3.2597(1)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.06	12/12/2025		M			1,700	(2)	05/06/2031	Common Stock	1,700	$0	365,186	D

Explanation of Responses:

1. The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.25 to $3.275. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

2. The stock options are fully vested.

Remarks:

	/s/ Randall Moreadith	12/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Serina Therapeutics (SER) report for its Chief Scientific Officer?

The Chief Scientific Officer, Randall Moreadith, reported transactions dated 12/12/2025 involving Serina Therapeutics common stock. He acquired 1,700 shares at $0.06 per share and sold 1,700 shares at a weighted average price of $3.2597.

How many Serina Therapeutics shares does the reporting person own after the transaction?

After the reported transactions, the filing shows that the Chief Scientific Officer directly owns 0 shares of Serina Therapeutics common stock and beneficially owns 365,186 derivative securities (stock options).

At what prices were the Serina Therapeutics (SER) shares sold in this insider transaction?

The sale of 1,700 shares of Serina Therapeutics common stock is reported at a weighted average price of $3.2597 per share. The shares were sold in multiple trades at prices ranging from $3.25 to $3.275.

What stock options does the Serina Therapeutics CSO hold after the reported trades?

The report lists a stock option (right to buy) with an exercise price of $0.06 per share and an expiration date of 05/06/2031. Following the transaction, the Chief Scientific Officer beneficially owns 365,186 such derivative securities, and the stock options are described as fully vested.

What is the transaction date disclosed in this Serina Therapeutics insider report?

The earliest transaction date disclosed for the reported insider activity is 12/12/2025, and the same date appears in both the common stock and stock option transaction tables.

What is the relationship of the reporting person to Serina Therapeutics (SER)?

The reporting person is identified as an officer of Serina Therapeutics, Inc., with the title Chief Scientific Officer. The officer check box is marked, while the director and 10% owner boxes are not marked.